Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Financial Performance - Teva Pharmaceutical Industries Ltd. reported total revenue of $4.71 billion for Q4 2025, exceeding analysts' expectations of $4.37 billion, with an 11% year-over-year increase in U.S. dollars or 9% in local currency [1] - The company achieved adjusted earnings of 96 cents per share, surpassing the consensus estimate of 68 cents and up from 71 cents reported a year ago [4] Revenue Drivers - The revenue increase was primarily driven by development milestone payments related to Phase 3 studies for duvakitug and higher revenues from key innovative products, partially offset by lower proceeds from certain product rights and reduced revenues from the International Markets segment due to a divestment in Japan [2] - Key brands collectively generated approximately $1 billion in revenues for the first time in Q4 2025, with Austedo sales increasing 34% to $2.26 billion, Ajovy sales reaching $673 million (+30% LC YoY), and Uzedy revenues at $191 million, up 63% [3][4] Future Outlook - For fiscal year 2026, Teva expects adjusted earnings of $2.57-$2.77 per share, compared to the Street estimate of $2.73 [5] - The company anticipates total sales between $16.4 billion and $16.8 billion, including specific revenue projections for Austedo, Ajovy, and Uzedy [6] - Teva's pipeline for 2026 includes multiple late-stage readouts across immunology and neurology, with potential value exceeding $10 billion [7]